Cardiotoxin Analog (CTX) IV 6-12 |
| Katalog-Nr.GC35609 |
Cardiotoxin Analog (CTX) IV 6-12 ist ein Teilpeptid von Cardiotoxin Analog (CTX) IV.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 115722-23-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cardiotoxin Analog (CTX) IV 6-12 is a peptide fragment of cyclophosphamide analog (CTX) IV, derived from the venom of Naja atra, and is a unique cardiotoxin analog[1]. Cardiotoxin Analog (CTX) IV 6-12 has a three-finger ring structure similar to neurotoxins and muscarinic toxins and has cytolytic effects on many cells[2]. Cardiotoxin Analog (CTX) IV 6-12 can cause depolarization and contraction of smooth and skeletal muscles, as well as depolarization of nerve cells[3]. Cardiotoxin Analog (CTX) IV 6-12 is able to induce membrane fusion of vesicles formed by phospholipids such as cardiolipin or sphingomyelin[4]. Cardiotoxin Analog (CTX) IV 6-12 is the only cardiotoxin isoform known to date that has a positively charged residue at the N-terminal amino acid[5]. CTX IV differs from CTX II only by the presence of arginine in place of a leucine residue at position 1[6].
References:
[1] Kaneda N, Sasaki T, Hayashi K. Primary structures of cardiotoxin analogues II and IV from the venom of Naja naja atra[J]. Biochimica et Biophysica Acta (BBA)-Protein Structure, 1977, 491(1): 53-66.
[2] Wu W G. Diversity of cobra cardiotoxin[J]. Journal of Toxicology: Toxin Reviews, 1997, 16(3): 115-134.
[3] Harvey A L. Cardiotoxins from cobra venoms: possible mechanisms of action[J]. Journal of Toxicology: Toxin Reviews, 1985, 4(1): 41-69.
[4] Forouhar F, Huang W N, Liu J H, et al. Structural basis of membrane-induced cardiotoxin A3 oligomerization[J]. Journal of Biological Chemistry, 2003, 278(24): 21980-21988.
[5] Jang J Y, Kumar T K S, Jayaraman G, et al. Comparison of the hemolytic activity and solution structures of two snake venom cardiotoxin analogues which only differ in their N-terminal amino acid[J]. Biochemistry, 1997, 36(48): 14635-14641.
[6] Kumar T K S, Pandian S T K, Jayaraman G, et al. Understanding the structure, function and folding of cobra toxins[J]. PROCEEDINGS-NATIONAL SCIENCE COUNCIL REPUBLIC OF CHINA PART A PHYSICAL SCIENCE AND ENGINEERING, 1999, 23: 1-19.
| Cas No. | 115722-23-1 | SDF | |
| Formula | C48H70N10O7 | M.Wt | 899.13 |
| Löslichkeit | 100 mg/ml in water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1122 mL | 5.5609 mL | 11.1219 mL |
| 5 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL |
| 10 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *